Aluminum Oxide Antimony Trisulfide Barium Carbonat
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aluminum Oxide Antimony Trisulfide Barium Carbonat
- Multi-Component Homeopathic Compound: Unable to Complete Repurposing Evaluation
Multi-Component Homeopathic Compound: Unable to Complete Repurposing Evaluation
One-Sentence Summary
This submission contains a 20-component compound formula — including ingredients such as Epinephrine, Quinine Sulfate, Lithium Carbonate, and multiple botanical, mineral, and animal-derived substances — which is consistent in profile with a homeopathic or traditional combination preparation. No TxGNN drug repurposing predictions were generated for this compound, and the product has no regulatory approval record in Taiwan. Due to multiple critical data gaps and the absence of a unified drug identifier, a standard repurposing evaluation cannot be completed at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available |
| Predicted New Indication | Not available — no TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (no predictions, no supporting studies identified) |
| Market Status | Not marketed (Taiwan) |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why Evaluation Cannot Proceed
Currently, detailed mechanism of action data is not available. This product is a 20-ingredient compound formula spanning four material categories:
| Category | Ingredients |
|---|---|
| Chemical / Mineral | Aluminum Oxide, Antimony Trisulfide, Barium Carbonate, Gold Monosulfide, Graphite, Lithium Carbonate, Selenium |
| Botanical | Conium maculatum (hemlock), Dioscorea villosa (wild yam), Guaiacum officinale, Lilium lancifolium, Solanum tuberosum, Toxicodendron vernix, Viola odorata |
| Pharmaceutical | Epinephrine, Quinine Sulfate |
| Animal-derived | Egg Phospholipids, Sepia officinalis juice (cuttlefish ink), Sus scrofa placenta (porcine placenta), Thyroid (bovine) |
TxGNN operates on individual drug entities mapped to DrugBank IDs through a knowledge graph. This multi-component mixture lacks a unified DrugBank identifier, making it incompatible with the standard single-entity prediction pipeline. Individual components such as Epinephrine (DB00668) and Quinine Sulfate (DB00468) do exist in DrugBank as separate entries, but the combination product as a whole has no recognized identity in the knowledge graph and cannot be scored.
The ingredient profile — particularly the use of highly diluted botanical toxins (Conium maculatum), mineral salts, and animal tissue extracts alongside conventional pharmaceuticals — is characteristic of classical homeopathic polypharmacy formulas (e.g., products registered under German homeopathic pharmacopoeia or HPUS standards). However, without a confirmed brand name, pharmacopoeial reference, or country-of-origin registration record, this interpretation cannot be confirmed.
Safety Considerations
No structured safety data was retrieved for this compound as a whole. Individual components carry the following known safety signals that warrant attention:
- Conium maculatum (poison hemlock): Highly toxic alkaloids (coniine, γ-coniceine); neuromuscular blockade risk even at low doses.
- Quinine Sulfate: Risk of cardiac arrhythmia (QT prolongation), cinchonism, and severe hypersensitivity reactions (thrombocytopenia, hemolysis).
- Epinephrine: Cardiovascular contraindications (hypertension, arrhythmia, coronary artery disease); interaction risk with MAOIs, tricyclic antidepressants, and beta-blockers.
- Lithium Carbonate: Narrow therapeutic index; renal and thyroid toxicity; significant drug-drug interactions.
- Toxicodendron vernix (poison sumac): Contact dermatitis and systemic sensitization risk.
- Barium Carbonate: Systemic barium toxicity (hypokalemia, cardiac and skeletal muscle paralysis) at non-homeopathic doses.
A component-by-component safety review is strongly recommended before any clinical evaluation of this compound is considered.
Conclusion and Next Steps
Decision: Hold
Rationale: This compound cannot be evaluated through the standard TxGNN drug repurposing pipeline. The absence of a unified DrugBank identifier, zero regulatory approval records, missing MOA data, and the multi-component nature of the formula collectively prevent scoring, evidence mapping, or safety profiling under the current framework.
To proceed, the following is needed:
- Clarify product identity: Obtain the official brand name, pharmacopoeial registration (e.g., HPUS, HAB, or equivalent), and country-of-origin regulatory filing. This is a blocking prerequisite.
- Establish analytical strategy: Decide whether to evaluate this product as a unified compound (requires finding a reference DrugBank/NDA entry) or decompose it into individual active components for parallel repurposing analysis.
- Map individual components: For a component-level analysis, map Epinephrine, Quinine Sulfate, Lithium Carbonate, and other pharmacologically active ingredients to their respective DrugBank IDs and run separate TxGNN queries.
- Retrieve package insert / prescribing information: Especially critical for Conium maculatum, Quinine Sulfate, and Epinephrine to address the Blocking data gap (DG001).
- Obtain original indication(s): Without knowing what this product was originally intended to treat, the repurposing concept cannot be framed.
- Confirm homeopathic classification: If this is a registered homeopathic product, a separate evaluation framework for homeopathic repurposing may be more appropriate than the TxGNN pipeline designed for conventional pharmaceuticals.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.